Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company.

A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Wednesday, October 28th. Pareto Securities upgraded shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a research report on Tuesday, October 27th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Finally, Nordea Equity Research lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, October 22nd.

Swedish Orphan Biovitrum Price Performance

BIOVF opened at $45.72 on Friday. The business’s fifty day simple moving average is $45.82 and its 200-day simple moving average is $44.43. Swedish Orphan Biovitrum has a 12-month low of $34.88 and a 12-month high of $49.03. The company has a market capitalization of $16.27 billion, a price-to-earnings ratio of 20.97 and a beta of 0.48. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.